ETPrime

Mankind Pharma Share Price

  • 2,455.309.61 (0.40%)
  • Volume: 4,41,612
  • Closed
  • Last Updated On: 16 Oct, 2025, 03:44 PM IST
High: "3160.00",Open: "2809.75",Low: "2150.00",
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Loading...
Mankind Pharma Share Price
  • 2,455.309.61 (0.40%)
  • Volume: 4,41,612
Advertisment
Stock Recommendations

  • Potential
    Upside

  • 1 Year
    Target

BUY

Mean Recos by
16 Analysts

0

2

4

5

5

Strong Sell

Sell

Hold

Buy

Strong Buy

Unlock Potential Upside
Stock Reports Plus

/10

Stock Score

View Report
Earnings
Fundamentals
Relative Valuation
Risk
Price Momentum
No Rating (NR)
Negative
Neutral
Positive
Unlock Stock Score

Key Metrics

PE Ratio
(x)		53.54
EPS - TTM
(₹)		45.86
MCap
(₹ Cr.)		1,01,344
Sectoral MCap Rank
6
PB Ratio
(x)		6.93
Div Yield
(%)		0.00
Face Value
(₹)		1.00
Beta

Beta

1 Month-
3 Months-
6 Months-
1 Year-
3 Years-

-
VWAP
(₹)		2,450.89
52W H/L
(₹)
3,054.80 / 2,115.10

Mankind Pharma share price insights

  • In the last 2 years, only 1.64 % trading sessions saw intraday gains higher than 5 % .

  • Company has spent 3.52% of its operating revenues towards interest expenses and 22.06% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)

  • Mankind Pharma Ltd. share price moved up by 0.40% from its previous close of Rs 2,445.70. Mankind Pharma Ltd. stock last traded price is 2,455.30

    Share PriceValue
    Today/Current/Last2,455.30
    Previous Day2,445.702,445.70

InsightsMankind Pharma

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Mankind Pharma Share Price Returns

    1 Day0.4%
    1 Week-0.97%
    1 Month-4.46%
    3 Months-6.48%
    1 Year-9.45%
    3 YearsN.A.
    5 YearsN.A.

    ET Stock ScreenersTop Score Companies

    Check whether Mankind Pharma belongs to analysts' top-rated companies list?

    View Stock Screeners

    Mankind Pharma News & Analysis

    View all Mankind Pharma Share News & Announcements

    Mankind Pharma Share Recommendations

    Recent Recos

    BUY

    Current

    Mean Recos by 16 Analysts

    Strong
    Sell    SellHoldBuyStrong
    Buy
    • Target₹2760
    • OrganizationMotilal Oswal Financial Services
    • BUY
    • Target₹2650
    • OrganizationMotilal Oswal Financial Services
    • BUY

    Analyst Trends

    RatingsCurrent1 Week Ago1 Month Ago3 Months Ago
    Strong Buy5555
    Buy5556
    Hold4443
    Sell2222
    Strong Sell----
    # Analysts16161616
    View all Stock Recommendations

    Mankind Pharma Financials

    • Insights

      • Employee & Interest Expense

        Company has spent 3.52% of its operating revenues towards interest expenses and 22.06% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)
      Quarterly | AnnualJun 2025Mar 2025Dec 2024Sep 2024Jun 2024
      Total Income3,650.233,330.703,307.323,185.942,994.02
      Total Income Growth (%)9.590.713.816.4118.19
      Total Expenses2,942.262,627.052,592.502,332.092,319.40
      Total Expenses Growth (%)12.001.3311.170.5518.66
      EBIT707.97703.65714.82853.85674.62
      EBIT Growth (%)0.61-1.56-16.2826.5716.61
      Profit after Tax (PAT)438.32420.77380.23653.47536.49
      PAT Growth (%)4.1710.66-41.8121.8013.85
      EBIT Margin (%)19.4021.1321.6126.8022.53
      Net Profit Margin (%)12.0112.6311.5020.5117.92
      Basic EPS (₹)10.6210.209.4516.3113.39
      Quarterly | AnnualJun 2025Mar 2025Dec 2024Sep 2024Jun 2024
      Total Income2,605.582,345.912,466.392,635.502,498.09
      Total Income Growth (%)11.07-4.88-6.425.5011.69
      Total Expenses1,965.221,754.911,742.671,863.131,914.46
      Total Expenses Growth (%)11.980.70-6.47-2.6813.44
      EBIT640.36591.00723.72772.37583.63
      EBIT Growth (%)8.35-18.34-6.3032.346.33
      Profit after Tax (PAT)412.76382.46416.38634.43513.49
      PAT Growth (%)7.92-8.15-34.3723.5513.06
      EBIT Margin (%)24.5825.1929.3429.3123.36
      Net Profit Margin (%)15.8416.3016.8824.0720.56
      Basic EPS (₹)10.009.2710.3515.8312.82
      Quarterly | Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Revenue12,744.2310,615.638,878.007,977.586,385.38
      Total Revenue Growth (%)20.0519.5711.2924.946.86
      Total Expenses10,240.148,231.497,219.186,017.434,705.45
      Total Expenses Growth (%)24.4014.0219.9727.883.43
      Profit after Tax (PAT)1,990.961,912.901,281.861,433.481,265.43
      PAT Growth (%)4.0849.23-10.5813.2822.81
      Operating Profit Margin (%)24.0323.3919.4625.9427.35
      Net Profit Margin (%)16.3018.5014.6518.4220.36
      Basic EPS (₹)49.2847.7532.0035.7831.59
      Quarterly | Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Revenue9,991.019,531.458,289.947,419.775,677.68
      Total Revenue Growth (%)4.8214.9811.7330.6816.15
      Total Expenses7,685.027,271.886,727.105,622.234,237.47
      Total Expenses Growth (%)5.688.1019.6532.6816.95
      Profit after Tax (PAT)1,945.481,823.411,248.261,335.131,084.37
      PAT Growth (%)6.6946.08-6.5123.1213.16
      Operating Profit Margin (%)28.1924.5419.5725.3726.18
      Net Profit Margin (%)20.4819.6815.3518.3919.61
      Basic EPS (₹)48.1645.5231.1633.3327.07

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Assets27,759.5311,963.259,715.459,147.746,372.63
      Total Assets Growth (%)132.0423.146.2143.5525.61
      Total Liabilities13,191.352,387.472,092.162,831.431,509.74
      Total Liabilities Growth (%)452.5314.12-26.1187.547.71
      Total Equity14,568.189,575.797,623.296,316.314,862.89
      Total Equity Growth (%)52.1425.6120.6929.8932.45
      Current Ratio (x)1.233.102.321.682.89
      Total Debt to Equity (x)0.590.020.020.140.05
      Contingent Liabilities5,304.33329.78167.78211.93183.16
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Assets23,828.3211,417.719,371.128,412.855,880.33
      Total Assets Growth (%)108.7021.8411.3943.0729.78
      Total Liabilities9,188.051,793.901,587.212,344.071,146.06
      Total Liabilities Growth (%)412.1813.02-32.29104.5330.29
      Total Equity14,640.279,623.817,783.916,068.774,734.27
      Total Equity Growth (%)52.1323.6428.2628.1929.65
      Current Ratio (x)1.153.452.481.462.86
      Total Debt to Equity (x)0.500.000.000.110.02
      Contingent Liabilities4,261.71449.91168.37275.47-

      All figures in Rs Cr, unless mentioned otherwise

      View Details

    • Insights

      • Increase in Cash from Investing

        Company has used Rs 12682.95 cr for investing activities which is an YoY increase of 509.26%. (Source: Consolidated Financials)
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Net Cash flow from Operating Activities2,413.382,152.451,813.30919.781,137.24
      Net Cash used in Investing Activities-12,682.95-2,081.69-1,054.13-1,369.14-1,222.21
      Net Cash flow from Financing Activities10,232.565.27-739.73604.62-7.81
      Net Cash Flow21.8777.1921.76155.73-92.40
      Closing Cash & Cash Equivalent403.88382.01304.82283.06127.33
      Closing Cash & Cash Equivalent Growth (%)5.7325.327.69122.31-42.05
      Total Debt/ CFO (x)3.510.090.090.950.21
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Net Cash flow from Operating Activities2,322.161,982.971,798.99812.291,022.33
      Net Cash used in Investing Activities-12,114.68-1,919.12-1,040.61-1,369.34-1,127.16
      Net Cash flow from Financing Activities9,845.34-8.68-710.41578.9288.87
      Net Cash Flow-11.3355.0747.9621.87-15.96
      Closing Cash & Cash Equivalent200.29189.20134.1344.4561.53
      Closing Cash & Cash Equivalent Growth (%)5.8641.06201.76-27.76-20.60
      Total Debt/ CFO (x)3.120.000.000.850.09

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Return on Equity (%)13.8920.4317.2423.2826.79
      Return on Capital Employed (%)13.2724.5621.6930.9433.87
      Return on Assets (%)7.1715.9813.1915.6719.85
      Interest Coverage Ratio (x)8.2883.9845.6337.2990.29
      Asset Turnover Ratio (x)0.610.950.880.981.01
      Price to Earnings (x)50.2548.31---
      Price to Book (x)6.989.83---
      EV/EBITDA (x)30.4232.40---
      EBITDA Margin (%)29.1127.2423.1928.0829.27
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Return on Equity (%)13.2818.9416.0322.0022.90
      Return on Capital Employed (%)13.5623.1420.0029.7730.16
      Return on Assets (%)8.1615.9713.3215.8718.44
      Interest Coverage Ratio (x)8.22177.8867.0444.77191.27
      Asset Turnover Ratio (x)0.540.890.911.021.06
      Price to Earnings (x)51.5550.51---
      Price to Book (x)6.839.56---
      EV/EBITDA (x)34.9935.21---
      EBITDA Margin (%)32.1727.9722.8827.0427.60

    Financial InsightsMankind Pharma

    • Income (P&L)
    • Cash Flow

      • Employee & Interest Expense

        Company has spent 3.52% of its operating revenues towards interest expenses and 22.06% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)

      • Increase in Cash from Investing

        Company has used Rs 12682.95 cr for investing activities which is an YoY increase of 509.26%. (Source: Consolidated Financials)

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Mankind Pharma Share Price Forecast

    • Get multiple analysts’ prediction on Mankind Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Mankind Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Mankind Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    Mankind Pharma Technicals

    • Bullish / Bearish signals for Mankind Pharma basis selected technical indicators and moving average crossovers.

      5 Day EMA Crossover

      Bullish signal on daily chart

      Appeared on: 16 Oct 2025

      5D EMA: 2451.40

      Last 4 Buy Signals:9 Oct 2025
      Date7 days Gain/Loss %
      9 Oct 20250.87%
      7 Oct 20250.52%
      18 Sep 20251.35%
      15 Sep 20250.50%

      Average price gain of 3.25% within 7 days of Bullish signal in last 5 years

      Heikin-Ashi Changeover

      Bullish indication on daily chart

      • Prev. Close Price

        2453.08

      • LTP

        2455.30

      Formed on:16 Oct 2025

      On daily price chart, Heikin-Ashi candle changed from Red to Green

    • 43%
      Positive Movement since
      1st Jan 2005 on basis
      57%
      Negative Movement since
      1st Jan 2005 on basis
      Exclude

    • Pivot Levels

      R1R2R3PIVOTS1S2S3
      Classic2468.302481.302510.802451.802438.802422.302392.80

      Average True Range

      5 DAYS14 DAYS28 DAYS
      ATR41.1349.5255.59

    Mankind Pharma Peer Comparison

      • CHART
      • TABLE

      • Choose from Peers

          Choose from Stocks

          • 1D
          • 1W
          • 1M
          • 3M
          • 6M
          • 1Y
          • 5Y
          Loading...

        • Ratio Performance

          NAMEP/E (x)P/B (x)ROE %ROCE %ROA %Rev CAGR [3Yr]OPMNPMBasic EPSCurrent RatioTotal Debt/ Equity (x)Total Debt/ CFO (x)
          Mankind Pharma53.546.9613.8913.277.1716.7224.0316.3749.281.230.593.51
          Divis Labs75.9911.7114.6318.8512.932.2731.1723.4082.536.940.000.00
          Cipla23.514.0516.9021.5714.108.7324.9819.2065.294.250.000.02
          Torrent Pharma59.7415.7625.1728.7112.759.7525.6116.5956.471.190.401.17
          Dr. Reddys18.223.0516.8521.8111.4415.1124.3217.4767.891.920.120.90
          Add More
          Annual Ratios (%)

          Choose from Peers

          • Cadila Healthcare
          • Lupin
          • Alkem Labs
          • Aurobindo Pharma
          • Glenmark Pharma

          Choose from Stocks

            See All Parameters

          Peers InsightsMankind Pharma

            Do you find these insights useful?

            • hate it

            • meh

            • love it

            Mankind Pharma Shareholding Pattern

            • Loading...
              Showing Mankind Pharma Shareholding as on Sep 2025
              CategorySep 2025Jun 2025Mar 2025Dec 2024
              Promoters72.6772.6872.7072.71
              Pledge0.000.000.000.00
              FII12.8313.0712.9213.34
              DII11.8711.4611.4411.05
              Mutual Funds7.787.347.677.83
              Others2.622.782.932.90
            • Showing Shareholding as on Sep 2025
              CategoryNo. of SharesPercentage% Change QoQ
              Promoters29,99,60,61272.67 %-0.01
              Pledge00.00 %0.00
              FII5,29,81,12712.83 %-0.24
              DII4,90,46,28911.87 %0.41
              MF3,21,27,0247.78 %0.44
              Others1,07,70,4622.62 %-0.15

            Mankind Pharma MF Ownership

            MF Ownership as on 30 September 2025

            View all Mutual Fund Schemes
            Top Searches:
            Mankind Pharma News Mankind Pharma Quarterly Results Mankind Pharma Dividend Mankind Pharma Q1 ResultsMankind Pharma Q2 ResultsMankind Pharma Q3 ResultsMankind Pharma Q4 Results

            Mankind Pharma Corporate Actions

            • Meeting DateAnnounced onPurposeDetails
              Aug 07, 2025Jul 03, 2025AGM-
              Jul 31, 2025Jul 14, 2025Board MeetingQuarterly Results & Interim Dividend
              May 21, 2025May 08, 2025Board MeetingAudited Results
              Jan 23, 2025Jan 13, 2025Board MeetingQuarterly Results
              Dec 24, 2024Nov 21, 2024POM-
            • TypeDividendDividend per ShareEx-Dividend DateAnnounced on
              Interim100%1.0Aug 08, 2025Jul 31, 2025

            • No other corporate actions details are available.

            About Mankind Pharma

            Mankind Pharma Ltd., incorporated in the year 1991, is a Small Cap company (having a market cap of Rs 1,01,344.59 Crore) operating in Pharmaceuticals sector. Mankind Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services for the year ending 31-Mar-2025. Show More

            • Executives

            • Auditors

            • RJ

              Ramesh Juneja

              Chairman & Wholetime Director
              RJ

              Rajeev Juneja

              Vice Chairman & Mng.Director
              SA

              Sheetal Arora

              Chief Executive Officer
              SK

              Satish Kumar Sharma

              Whole Time Director
              Show More
            • Bhagi Bhardwaj Gaur & Co
              S R Batliboi & Co. LLP
              Goel Gaurav & Co.

            Industry

            Pharma - Indian

            Key Indices Listed on

            Nifty Midcap 100, Nifty 200, Nifty 500, + 23 more

            Address

            208, Okhla Industrial Estate,Phase-III,New Delhi, Delhi - 110020

            Contact

            [email protected]

            http://www.mankindpharma.com

            More Details

            FAQs about Mankind Pharma share

            • 1. What is Mankind Pharma share price and what are the returns for Mankind Pharma share?
              Mankind Pharma share price is Rs 2,455.30 as on 16 Oct, 2025, 03:57 PM IST. Mankind Pharma share price is up by 0.40% based on previous share price of Rs 2,438.1. Mankind Pharma share price trend:
              • Last 12 Months: Mankind Pharma share price moved down 9.45%
              • Last 3 Years: Mankind Pharma Share price moved remain unchanged by N.A.
            • 2. What are the returns for Mankind Pharma share?
              Return Performance of Mankind Pharma Shares:
              • 1 Week: Mankind Pharma share price moved down by 0.97%
              • 6 Month: Mankind Pharma share price moved down by 2.57%
            • 3. What has been highest price of Mankind Pharma share in last 52 weeks?
              Mankind Pharma share price saw a 52 week high of Rs 3,054.80 and 52 week low of Rs 2,115.10.
            • 4. What's the market capitalization of Mankind Pharma?
              Market Capitalization of Mankind Pharma stock is Rs 1,01,345 Cr.
            • 5. What is the PE & PB ratio of Mankind Pharma?
              The PE ratio of Mankind Pharma stands at 53.33, while the PB ratio is 6.93.

            Trending in Markets

            Top Gainers As on 03:59 PM | 16 Oct 2025

            BLS Int. Services324.50
            45.95 (16.50%)
            Craftsman Automation6,800.50
            376.50 (5.87%)
            Oberoi Realty1,687.10
            85.70 (5.36%)
            Apar Industries8,784.50
            429.00 (5.14%)
            Ola Electric Mobilit55.38
            2.64 (4.99%)

            Top Losers As on 03:59 PM | 16 Oct 2025

            KEI Industries4,172.60
            -248.00 (-5.62%)
            Anant Raj633.35
            -29.20 (-4.41%)
            Netweb Technologies3,760.20
            -172.21 (-4.38%)
            Tata Investment906.00
            -35.00 (-3.72%)
            Max Financial1,552.40
            -56.70 (-3.53%)

            DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

            DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

            By using this site, you agree to the Terms of Service and Privacy Policy.

            Business News›Markets›Stocks›Stock Price Quotes›Mankind Pharma Share Price
            The Economic Times
            BrowseCompanies: